Cargando…
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to ensure sufficient exposure for clinical activity while minimizing toxicity. These agents frequently have complex pharmacology, and combination therapy may cause schedule-specific effects and interactions. We re...
Autores principales: | Mould, DR, Walz, A-C, Lave, T, Gibbs, JP, Frame, B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369756/ https://www.ncbi.nlm.nih.gov/pubmed/26225225 http://dx.doi.org/10.1002/psp4.16 |
Ejemplares similares
-
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development
por: Mould, D R, et al.
Publicado: (2012) -
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods
por: Mould, D R, et al.
Publicado: (2013) -
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development:
Part 3—Introduction to Pharmacodynamic Modeling Methods
por: Upton, R N, et al.
Publicado: (2014) -
Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development
por: Overgaard, RV, et al.
Publicado: (2015) -
Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure‐Response Analyses Underutilized?
por: Jones, Aksana K., et al.
Publicado: (2019)